Compare Stocks: NWBO, FBRX, CVAC, and LXRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CVAC CureVac	$4.66	$4.66	$3.13 ▼ $5.72	$1.05B	1.77	992,546 shs	N/A
FBRX Forte Biosciences	$76.79	$37.32	$9.91 ▼ $77.20	$1.07B	2.6	2.17 million shs	1.16 million shs
LXRX Lexicon Pharmaceuticals	$2.47	$2.20	$1.02 ▼ $2.68	$1.10B	1.08	2.88 million shs	3.09 million shs
NWBO Northwest Biotherapeutics	$0.18	$0.18	$0.14 ▼ $0.37	$309.93M	-0.6	3.49 million shs	8.23 million shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CVAC CureVac	0.00%	0.00%	0.00%	0.00%	-14.34%
FBRX Forte Biosciences	0.00%	+0.25%	+74.84%	+195.35%	+654.32%
LXRX Lexicon Pharmaceuticals	0.00%	+6.93%	+11.26%	+6.93%	+128.70%
NWBO Northwest Biotherapeutics	0.00%	+11.95%	+3.15%	-28.50%	-25.97%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CVAC CureVac	$4.66	$4.66	$3.13 ▼ $5.72	$1.05B	1.77	992,546 shs	N/A
FBRX Forte Biosciences	$76.79	$37.32	$9.91 ▼ $77.20	$1.07B	2.6	2.17 million shs	1.16 million shs
LXRX Lexicon Pharmaceuticals	$2.47	$2.20	$1.02 ▼ $2.68	$1.10B	1.08	2.88 million shs	3.09 million shs
NWBO Northwest Biotherapeutics	$0.18	$0.18	$0.14 ▼ $0.37	$309.93M	-0.6	3.49 million shs	8.23 million shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CVAC CureVac	0.00%	0.00%	0.00%	0.00%	-14.34%
FBRX Forte Biosciences	0.00%	+0.25%	+74.84%	+195.35%	+654.32%
LXRX Lexicon Pharmaceuticals	0.00%	+6.93%	+11.26%	+6.93%	+128.70%
NWBO Northwest Biotherapeutics	0.00%	+11.95%	+3.15%	-28.50%	-25.97%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CVAC CureVac	1.00	Sell	N/A	N/A
FBRX Forte Biosciences	2.14	Hold	$72.50	-5.59% Downside
LXRX Lexicon Pharmaceuticals	2.25	Hold	$4.55	84.21% Upside
NWBO Northwest Biotherapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest NWBO, FBRX, CVAC, and LXRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/3/2026	LXRX Lexicon Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/28/2026	FBRX Forte Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	FBRX Forte Biosciences	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$74.00 ➝ $77.00
7/27/2026	FBRX Forte Biosciences	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$77.00
7/27/2026	FBRX Forte Biosciences	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/27/2026	FBRX Forte Biosciences	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/27/2026	FBRX Forte Biosciences	Brookline Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/23/2026	LXRX Lexicon Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/21/2026	FBRX Forte Biosciences	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$74.00
7/21/2026	FBRX Forte Biosciences	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$74.00
7/8/2026	FBRX Forte Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CVAC CureVac	$70.74M	14.78	$0.99 per share	4.73	$3.36 per share	1.39
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	$4.71 per share	N/A
LXRX Lexicon Pharmaceuticals	$49.80M	22.07	N/A	N/A	$0.30 per share	8.23
NWBO Northwest Biotherapeutics	$1.38M	224.59	N/A	N/A	($0.04) per share	-4.59

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CVAC CureVac	$175.50M	$0.72	6.47	N/A	N/A	199.92%	-23.03%	-19.09%	N/A
FBRX Forte Biosciences	-$69.38M	-$4.64	N/A	N/A	N/A	N/A	-106.17%	-85.50%	8/13/2026 (Estimated)
LXRX Lexicon Pharmaceuticals	-$50.34M	-$0.15	N/A	N/A	N/A	-147.38%	-37.53%	-24.96%	N/A
NWBO Northwest Biotherapeutics	-$60.16M	-$18.23	N/A	N/A	N/A	-2,931.73%	N/A	-79.26%	8/13/2026 (Estimated)

Latest NWBO, FBRX, CVAC, and LXRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	FBRX Forte Biosciences	-$0.8785	N/A	N/A	N/A	N/A	N/A
8/6/2026	Q2 2026	LXRX Lexicon Pharmaceuticals	-$0.0502	-$0.06	-$0.0098	-$0.07	$3.99 million	$0.69 million
5/11/2026	Q1 2026	FBRX Forte Biosciences	-$1.16	-$1.24	-$0.08	-$1.24	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CVAC CureVac	N/A	N/A	N/A	N/A	N/A
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	N/A
LXRX Lexicon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NWBO Northwest Biotherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CVAC CureVac	0.03	3.70	3.69
FBRX Forte Biosciences	N/A	2.75	2.75
LXRX Lexicon Pharmaceuticals	0.29	13.37	13.29
NWBO Northwest Biotherapeutics	N/A	0.07	0.07

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CVAC CureVac	17.26%
FBRX Forte Biosciences	77.63%
LXRX Lexicon Pharmaceuticals	74.70%
NWBO Northwest Biotherapeutics	0.04%

Insider Ownership

Company	Insider Ownership
CVAC CureVac	2.15%
FBRX Forte Biosciences	4.40%
LXRX Lexicon Pharmaceuticals	14.00%
NWBO Northwest Biotherapeutics	2.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CVAC CureVac	880	224.34 million	219.52 million	No Data
FBRX Forte Biosciences	5	13.89 million	13.28 million	Optionable
LXRX Lexicon Pharmaceuticals	140	444.96 million	382.66 million	Optionable
NWBO Northwest Biotherapeutics	20	1.69 billion	1.65 billion	Not Optionable

NWBO, FBRX, CVAC, and LXRX Headlines

Recent News About These Companies

Northwest Biotherapeutics Announces MOU for Collaboration With the Saudi Pharmaceutical Industries and Medical Appliance Company

August 6, 2026 | prnewswire.com

Northwest Biotherapeutics (OTCMKTS:NWBO) Share Price Crosses Below Two Hundred Day Moving Average - Should You Sell?

August 4, 2026 | americanbankingnews.com

NORTHWEST BIOTHRPUTCS INC by Northwest Biotherapeutics, Inc. Insider Trading Activity

July 18, 2026 | benzinga.com

Northwest Biotherapeutics, Inc.: Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax-L For Glioblastoma Using Individual Patient Level Data ...

July 8, 2026 | finanznachrichten.de

Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses

July 8, 2026 | prnewswire.com

Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting

July 2, 2026 | prnewswire.com

Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform

April 30, 2026 | prnewswire.com

Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic

April 21, 2026 | prnewswire.com

Northwest Biotherapeutics expands authorized common stock capacity

January 3, 2026 | msn.com

Northwest Biotherapeutics, Inc.: Northwest Biotherapeutics Announces That Construction Activities Are Under Way For the First Grade C Manufacturing Suite in the Sawston, UK ...

November 22, 2025 | finanznachrichten.de

Northwest Biotherapeutics Announces That Construction Activities Are Under Way For the First Grade C Manufacturing Suite in the Sawston, UK Facility

November 20, 2025 | prnewswire.com

Northwest Biotherapeutics Secures $5.5M Loan Agreement

October 31, 2025 | tipranks.com

Northwest Biotherapeutics, Inc.: Northwest Biotherapeutics Announces That Its Acquisition of Advent BioServices Ltd. Has Closed

October 24, 2025 | finanznachrichten.de

Northwest Biotherapeutics Announces That Its Acquisition of Advent BioServices Ltd. Has Closed

October 24, 2025 | prnewswire.com

Northwest Biotherapeutics Inc.

October 13, 2025 | barrons.com

Northwest Biotherapeutics, Inc.: Northwest Biotherapeutics Announces Agreement to Acquire Advent BioServices Ltd.

August 27, 2025 | finanznachrichten.de

Northwest Biotherapeutics Announces Agreement to Acquire Advent BioServices Ltd.

August 27, 2025 | prnewswire.com

Northwest Biotherapeutics announces passing of general counsel Les Goldman

August 19, 2025 | msn.com

Northwest Biotherapeutics Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman

August 18, 2025 | prnewswire.com

NWBO - Northwest Biotherapeutics Inc News - Morningstar

July 11, 2025 | morningstar.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

NWBO, FBRX, CVAC, and LXRX Company Descriptions

CureVac NASDAQ:CVAC

$4.66 0.00 (0.00%)

As of 08/7/2026

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Forte Biosciences NASDAQ:FBRX

$76.79 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$77.12 +0.33 (+0.43%)

As of 08:14 AM Eastern

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Lexicon Pharmaceuticals NASDAQ:LXRX

$2.47 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$2.44 -0.03 (-1.05%)

As of 07:49 AM Eastern

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Northwest Biotherapeutics OTCMKTS:NWBO

$0.18 0.00 (0.00%)

As of 08/7/2026 03:59 PM Eastern

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NWBO, FBRX, CVAC, and LXRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NWBO, FBRX, CVAC, and LXRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NWBO, FBRX, CVAC, and LXRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NWBO, FBRX, CVAC, and LXRX Company Descriptions

CureVac NASDAQ:CVAC

Forte Biosciences NASDAQ:FBRX

Lexicon Pharmaceuticals NASDAQ:LXRX

Northwest Biotherapeutics OTCMKTS:NWBO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NWBO, FBRX, CVAC, and LXRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NWBO, FBRX, CVAC, and LXRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NWBO, FBRX, CVAC, and LXRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NWBO, FBRX, CVAC, and LXRX Company Descriptions

CureVac NASDAQ:CVAC

Forte Biosciences NASDAQ:FBRX

Lexicon Pharmaceuticals NASDAQ:LXRX

Northwest Biotherapeutics OTCMKTS:NWBO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools